193 related articles for article (PubMed ID: 36947039)
1. Trends in the Use of Oral Anticoagulants for Adults With Venous Thromboembolism in the US, 2010-2020.
Iyer GS; Tesfaye H; Khan NF; Zakoul H; Bykov K
JAMA Netw Open; 2023 Mar; 6(3):e234059. PubMed ID: 36947039
[TBL] [Abstract][Full Text] [Related]
2. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
[TBL] [Abstract][Full Text] [Related]
3. Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017.
Lutsey PL; Walker RF; MacLehose RF; Alonso A; Adam TJ; Zakai NA
Res Pract Thromb Haemost; 2019 Oct; 3(4):668-673. PubMed ID: 31624786
[TBL] [Abstract][Full Text] [Related]
4. A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Nadkarni A; Vo L
J Manag Care Spec Pharm; 2018 Sep; 24(9):911-920. PubMed ID: 30156450
[TBL] [Abstract][Full Text] [Related]
5. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH
Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness and Safety of Oral Anticoagulants by Dementia Status in Older Patients With Atrial Fibrillation.
Lin KJ; Singer DE; Bykov K; Bessette LG; Mastrorilli JM; Cervone A; Kim DH
JAMA Netw Open; 2023 Mar; 6(3):e234086. PubMed ID: 36976562
[TBL] [Abstract][Full Text] [Related]
7. Impact of oral anticoagulation choice on healthcare utilization for the primary treatment of venous thromboembolism.
Lutsey PL; MacLehose RF; Claxton JS; Walker RF; Adam TJ; Alonso A; Zakai NA
Vasc Med; 2020 Dec; 25(6):549-556. PubMed ID: 32716254
[TBL] [Abstract][Full Text] [Related]
8. Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Time Trends and Treatment Patterns.
Ghanima W; Schultze A; Donaldson R; Brodin E; Halvorsen S; Graham S; Carroll R; Ulvestad M; Lambrelli D
Clin Ther; 2021 Jul; 43(7):1179-1190.e3. PubMed ID: 34083030
[TBL] [Abstract][Full Text] [Related]
9. Utilization outcomes of direct oral anticoagulants in Medicare patients.
Arora P; Muehrcke M; Russell M; Ghanekar S
Res Social Adm Pharm; 2023 Nov; 19(11):1424-1431. PubMed ID: 37429747
[TBL] [Abstract][Full Text] [Related]
10. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
[TBL] [Abstract][Full Text] [Related]
11. Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients.
Lutsey PL; Norby FL; Zakai NA; MacLehose RF; Chen LY; Shah S; Datta YH; Alonso A
Curr Med Res Opin; 2019 May; 35(5):837-845. PubMed ID: 30362847
[TBL] [Abstract][Full Text] [Related]
12. All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism.
Roetker NS; Lutsey PL; Zakai NA; Alonso A; Adam TJ; MacLehose RF
Thromb Haemost; 2018 Sep; 118(9):1637-1645. PubMed ID: 30103250
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation.
Shah S; Norby FL; Datta YH; Lutsey PL; MacLehose RF; Chen LY; Alonso A
Blood Adv; 2018 Feb; 2(3):200-209. PubMed ID: 29378726
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism.
Coons JC; Albert L; Bejjani A; Iasella CJ
Pharmacotherapy; 2020 Mar; 40(3):204-210. PubMed ID: 31968126
[TBL] [Abstract][Full Text] [Related]
17. Frailty, Home Time, and Health Care Costs in Older Adults With Atrial Fibrillation Receiving Oral Anticoagulants.
Lin KJ; Singer DE; Ko D; Glynn R; Najafzadeh M; Lee SB; Bessette LG; Cervone A; DiCesare E; Kim DH
JAMA Netw Open; 2023 Nov; 6(11):e2342264. PubMed ID: 37943558
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
19. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
[No Abstract] [Full Text] [Related]
20. Prescribing Trends of Oral Anticoagulants from 2010 to 2020 in Shanghai, China: A Retrospective Study.
Zhang C; Wang J; Yang Y; Ma EL; Lin HW; Liu BL; Gu ZC
Clin Appl Thromb Hemost; 2022; 28():10760296221132551. PubMed ID: 36250531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
